摘要
肝细胞癌(HCC)恶性程度高,发病率不断攀升,临床常用治疗手段疗效不佳,以免疫检查点为靶点的免疫疗法的出现给HCC患者带来了希望,并取得了质的飞跃。但单一免疫治疗临床应答率低,仅有小部分患者受益。免疫检查点抑制剂(ICIs)联合其他疗法的研究不断涌现,本文从HCC免疫逃逸、免疫治疗耐药机制入手,分析了ICIs在HCC治疗中应答率低的原因,对ICIs与多种治疗联用的现状进行梳理,以期通过药物联合使用,提高ICIs在HCC患者治疗中的疗效,改善患者的生存及预后。
Hepatocellular carcinoma(HCC)has a high degree of malignancy,a rising incidence rate,and poor efficacy of commonly used clinical treatments.The emergence of immunotherapy targeting immune checkpoints has brought hope to HCC patients and made a qualitative leap.However,the clinical response rate of single immunotherapy is low,and only a small number of patients benefit.Research on the combination of immune checkpoint inhibitors(ICIs)and other therapies are constantly emerging.This article starts with the immune escape and immune therapy resistance mechanisms of HCC,analyzes the reasons for the low response rate of ICIs in HCC treatment,and reviews the current situation of ICIs combined with multiple treatments.The aim is to improve the therapeutic effect of ICIs in HCC patients and improve their survival and prognosis through drug combination.
作者
何玲
刘喜平
HE Ling;LIU Xiping(Gansu Engineering Laboratory for New Products of Traditional Chinese Medicine,Gansu Key Laboratory of TCM Excavation and Innovative Transformation,Gansu University of Traditional Chinese Medicine,Lanzhou 730000,China)
出处
《中国免疫学杂志》
北大核心
2026年第3期742-748,共7页
Chinese Journal of Immunology
基金
国家自然科学基金项目(82260895)
甘肃省高校教师创新基金项目(2024A-085)
甘肃中医药大学博导专项基金项目(ZYXKBD-202207)。
关键词
肝细胞癌
免疫检查点抑制剂
联合治疗
应用
Hepatocellular carcinoma
Immune checkpoint inhibitors
Combination therapy
Appliance
